Use prophylactic antibiotic eye ointment in all newborns for gonococcal infection: USPSTF
The U.S. Preventive Services Task Force (USPSTF) reaffirms its recommendation for the use of an antibiotic ointment to prevent gonococcal eye infections in all newborns, a gonorrhoea infection that is transmitted from the mother to the newborn during delivery.
In the United States, the rate of gonococcal ophthalmia neonatorum was an estimated 0.4 cases per 100 000 live births per year from 2013 to 2017.1-4 Gonococcal ophthalmia neonatorum can cause corneal scarring, ocular perforation, and blindness as early as 24 hours after birth. In the absence of ocular prophylaxis, transmission rates of gonococcal infection from mother to newborn are 30% to 50%.
The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. This latest statement is a reaffirmation of its 2011 recommendation on prevention of gonococcal ophthalmia neonatorum, a gonorrhea infection of the eye in newborns. This infection can spread to the cornea and cause blindness as early as 24 hours after birth. In the absence of prevention, transmission rates of gonococcal infection from mother to newborn are 30 percent to 50 percent.
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum.The USPSTF found convincing evidence that ocular prophylaxis of newborns with 0.5% erythromycin ophthalmic ointment can prevent gonococcal ophthalmia neonatorum.The USPSTF found convincing evidence that ocular prophylaxis of newborns with 0.5% erythromycin ophthalmic ointment is not associated with serious harms.
For more details click on the link: doi:10.1001/jama.2018.21367
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd